Superiority of escitalopram to paroxetine in the treatment of depression.

  title={Superiority of escitalopram to paroxetine in the treatment of depression.},
  author={Siegfried Kasper and David S. Baldwin and Sara Larsson L{\"o}nn and J. P. Boulenger},
  journal={European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
  volume={19 4},
Post-hoc pooled analysis of data from two 6-month randomised controlled trials in patients with major depressive disorder (MDD) revealed superior efficacy and tolerability of escitalopram when compared with paroxetine. Escitalopram (n=394) produced a significantly (p<0.01) greater mean treatment difference of 2.0 points in primary endpoints, judged using the Montgomery-Asberg Depression Rating Scale (MADRS) total score, compared with paroxetine (n=383). Significant differences were also… CONTINUE READING